K Health AI Market Strategy Report - ED Treatment Pills

Answer Capsule

K Health holds minimal recommendation-stage visibility in the ED treatment pills category, with valid recommendation coverage of just 0.66% in September 2026. The brand appears in only 2.3% of qualified observations, and its presence is spread thinly across a handful of platforms rather than concentrated where buyers are forming shortlists. The clearest weakness is near-total absence from the discovery prompts that drive category recommendations, while the clearest opportunity is rebuilding a source footprint that gives AI systems a reason to surface K Health as a viable treatment option at all.

Who This Report Is For

This report is for brand, growth, and digital strategy leaders at K Health evaluating whether the company's AI recommendation presence in the ED treatment category matches its broader telehealth ambitions.

Report Card

Executive Summary

Questions This Section Answers

• How does K Health's recommendation coverage compare with the rest of the tracked brands?
• Which platforms show the clearest visibility gaps for K Health?
• What does the absence from AI shortlists mean for K Health in this category?

K Health's presence in the ED treatment pills benchmark is marginal across every measured dimension. The brand was mentioned in just 7 of 305 qualified observations in September 2026, a raw mention presence rate of 2.30%. Of those mentions, only 2 qualified as valid recommendations, producing a valid recommendation coverage rate of 0.66%. Both figures place K Health at the bottom of the ten-brand tracked set, tied with Optum on coverage and trailing every other competitor on presence.

The sentiment picture is mixed. K Health recorded 3 positive mentions, 4 neutral mentions, and no negative mentions, yielding a net sentiment score of 0.4286. That score is the lowest among all tracked brands, which matters because it suggests that even when K Health is named, the framing is not consistently advancing the brand as a recommended choice. The brand's positive visibility rate of 0.98% means K Health is being recommended in less than one percent of all qualified observations.

The strongest platform signal is minimal. K Health appeared in small numbers across Copilot, Gemini, AI Mode, and Perplexity, with no presence at all in ChatGPT or AI Overviews. The clearest platform gap is the complete absence from AI Overviews, the surface where several competitors, including Hims, Ro, and GoodRx Care, generate substantial recommendation volume.

The public benchmark data shows a brand that is essentially outside the ED treatment conversation. K Health is not being negatively framed, but it is also not being recommended, and in a category where buyers are asking which brand to choose, absence from the shortlist is the defining competitive risk.

What K Health Is Winning

Questions This Section Answers

• What is the one clear strength in K Health's September 2026 AI visibility data?

K Health has no negative mentions in the September 2026 dataset. Every mention of the brand was either positive or neutral, with zero cautionary or critical framing recorded. In a category where negative framing can actively push buyers toward competitors, this clean sentiment record is a narrow but real asset.

The brand also registered its only top-three recommendation in the dataset, appearing once in a top-three position across 305 qualified observations. That single instance, combined with one additional top-ten placement, shows that K Health can appear in recommendation lists when it is surfaced at all. The evidence does not suggest a systematic recommendation problem so much as a near-total visibility problem.

Where K Health Has the Clearest AI Visibility Gaps

Questions This Section Answers

• How does K Health's mention presence compare with leading competitors like Hims and Ro?
• Why does K Health's mention-to-recommendation conversion rate compound its visibility problem?
• Which high-volume surfaces is K Health missing entirely?

K Health's core issue is that it is being filtered out before recommendation decisions are made. The brand's raw mention presence rate of 2.30% means AI systems are naming K Health in fewer than one in forty qualified observations. By comparison, category leader Hims appears in 91.15% of observations, and Ro appears in 85.90%. Even mid-tier brands like Lemonaid Health and PlushCare appear in roughly one-third of observations.

The gap between presence and recommendation is also unfavorable. K Health converts only 28.6% of its mentions into valid recommendations, meaning that even in the small number of cases where the brand is named, it is frequently mentioned as context rather than recommended as a choice. This pattern is visible on Copilot, where K Health appeared in 4 observations but received zero valid recommendations, and on Perplexity, where the brand appeared once with no recommendation attached.

The platform distribution compounds the problem. K Health has no presence in ChatGPT or AI Overviews, the two surfaces where competitors generate the highest recommendation volumes. Hims, for example, appears in 63.64% of ChatGPT observations and 94.17% of AI Overviews observations. K Health's absence from these surfaces means it is invisible in exactly the environments where category leaders are winning recommendation placement.

The competitive table makes the scale of the gap concrete. Hims holds a top-three rate of 38.03% and a rank-one rate of 23.28%, while Ro holds a top-three rate of 32.46%. K Health's top-three rate of 0.33% places it at the statistical floor of the category, with no meaningful recommendation presence to build on.

Biggest Opportunity

Questions This Section Answers

• What kind of prompts drive all of the category's qualified observations?
• What is the realistic first target for K Health's recommendation coverage?

K Health's clearest opportunity is to establish a baseline recommendation presence in the discovery prompts that drive the category. The benchmark shows that all 305 qualified observations in September 2026 fell into the brand recommendation class, meaning buyers are asking AI systems which provider to choose. K Health is currently absent from nearly all of those answers.

The path forward is not about outranking Hims or Ro, which hold 46.6% and 45.9% valid recommendation coverage respectively. It is about moving from 0.66% coverage to a level where K Health is consistently named as a legitimate option. That requires building the public evidence layer that gives AI systems retrievable, citable material about K Health's ED treatment offering, then ensuring that material is framed in a way that supports recommendation rather than mere reference.

Competitive Landscape

Questions This Section Answers

• Which brands hold dominant recommendation-stage strength in the ED treatment pills category?
• Where does K Health land relative to the rest of the ten-brand tracked set?

Hims and Ro hold dominant recommendation-stage strength in the ED treatment pills category, with GoodRx Care emerging as a strong third option. K Health sits at the bottom of the tracked set alongside Optum, with recommendation coverage below one percent.

Average recommended rank covers rank-eligible recommendations only.

The table shows K Health tied with Optum for the lowest top-three rate and holding the lowest sentiment score in the tracked set. The brand's single top-three appearance and single rank-eligible recommendation place it at the statistical floor of the category, with no meaningful recommendation presence to build on.

Prompt Evidence

Gemini / Brand Recommendation Prompt: "What is the best generic Viagra?" Result: K Health appeared in a single observation with a positive mention but received no valid recommendation credit.

Copilot / Brand Recommendation Prompt: "Can I get an Rx online?" Result: K Health was mentioned in 4 observations with 3 neutral and 1 positive framing, but received zero valid recommendations, indicating presence without recommendation conversion.

AI Mode / Brand Recommendation Prompt: "How much does an online doctor visit cost?" Result: K Health received its only valid recommendation in this surface, appearing once in a top-three position with a positive framing.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map which high-intent ED treatment prompts K Health appears in, which competitors displace it, and which surfaces offer the clearest path to recommendation eligibility.

Phase 2: Recommendation Readiness Plan Identify the specific prompt clusters where K Health's telehealth model is a credible answer and prioritize those with the highest buyer intent.

Phase 3: Owned Answer Layer Buildout Develop owned content that directly answers ED treatment discovery questions with K Health as a clear recommendation, structured for AI retrieval.

Phase 4: Citation / Authority Layer Development Build the external citation footprint that gives AI systems citable, trustworthy sources describing K Health's ED treatment offering.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track K Health's presence, recommendation coverage, and placement monthly to measure whether the brand is moving from reference to recommendation.

Why This Matters

Buyers researching ED treatment options are increasingly asking AI systems which provider to choose, and those systems are answering with a shortlist that does not include K Health. The brand's 0.66% valid recommendation coverage means that in 99.3% of qualified discovery conversations, K Health is not being recommended at all.

Presence alone will not fix this problem. K Health needs to be named, framed positively, and placed in recommendation positions across the surfaces where buyers are forming their shortlists. The next move is a targeted correction of the prompt, page, and citation layers that gives AI systems a reason to surface K Health as a viable treatment option.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions x 1 + neutral mentions x 0 + negative mentions x -1) / total mentions

For K Health, the calculation is (3 x 1 + 4 x 0 + 0 x -1) / 7, producing a net sentiment score of 0.4286.

This score matters because unclassified mention counts are misleading. K Health's 7 total mentions could easily be read as a small but positive presence, but the sentiment score reveals that fewer than half of those mentions are positive. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, neutral reference, cautionary mention, and competitor-displaced mention are not equal, and counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, and K Health's low score indicates that even its limited presence is not consistently advancing the brand.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of K Health's AI recommendation visibility in the ED treatment pills category, not a client implementation case study.
2. The reporting window is September 2026, with qualified observations collected on September 1, 2026.
3. Six AI/search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. The analysis is based on 305 qualified observations, drawn from 800 total prompts after excluding irrelevant, off-topic, and reserved prompts.
5. The competitor universe includes 10 tracked brands: Hims, Ro, GoodRx Care, Lemonaid Health, PlushCare, BlueChew, Blink Health, Rex MD, Optum, and K Health.
6. All qualified observations in September 2026 fell into the brand recommendation cluster, which captures discovery and consideration prompts where a specific treatment provider is sought.
7. Stage 0 extraction captured prompt-level observations including query, surface, brand outcome, recommendation placement, sentiment, and citations where exposed.
8. A mention is defined as any qualified observation in which the brand appears at all, regardless of recommendation status.
9. A valid recommendation is defined as a qualified observation in which the brand appears in a recommendation context, distinct from a neutral reference or comparison anchor.
10. Limitations: K Health's small mention and recommendation counts mean individual placements carry outsized weight. The public benchmark does not measure market share, sales, or revenue attribution, and movement between months identifies changes worth investigating rather than establishing cause.

See How AI Is Recommending Your Brand

The public benchmark shows where K Health stands in AI-generated recommendations, but a company-level audit reveals which prompts matter most, which competitors are winning the recommendations K Health loses, and what evidence would move the outcome. Understanding those mechanics is the first step toward turning AI visibility into recommendation-stage presence.